NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals (NRXP) shows no detected cyber incidents or red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability in the near term. However, absence of recent signals does not indicate absence of risk—our analysis captures only the last three months. The full $49 Report extends visibility to 12 months of SEC filings, quantifies dilution risk through equity issuance patterns, maps financing history and runway, and applies AI-driven signals for clinical, regulatory, and market pressures. The full $49 Report adds historical context, dilution scoring, and forward risk indicators you won't find in standard filings.